Show simple item record

dc.contributor.authorLucero, Emilianoen_GB
dc.contributor.authorCollin, Simon Men_GB
dc.contributor.authorGomes, Sujiten_GB
dc.contributor.authorAkter, Fatimaen_GB
dc.contributor.authorAsad, Asaduzzamen_GB
dc.contributor.authorKumar Das, Asishen_GB
dc.contributor.authorRitmeijer, Koerten_GB
dc.date.accessioned2015-04-23T20:39:53Z
dc.date.available2015-04-23T20:39:53Z
dc.date.issued2015-04-02
dc.identifier.citationEffectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh. 2015, 9 (4):e0003699 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735
dc.identifier.pmid25837313
dc.identifier.doi10.1371/journal.pntd.0003699
dc.identifier.urihttp://hdl.handle.net/10144/550531
dc.description.abstractBangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15mg/kg Liposomal Amphotericin-B (AmBisome) in three equal doses of 5mg/kg. The main objective of this study was to analyze the effectiveness and safety of this regimen after a 12 month follow-up period by retrospective analysis of routinely collected program data. A secondary objective was to explore risk factors for relapse.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.titleEffectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladeshen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB
refterms.dateFOA2019-03-04T12:19:14Z
html.description.abstractBangladesh is one of the endemic countries for Visceral Leishmaniasis (VL). Médecins Sans Frontières (MSF) ran a VL treatment clinic in the most endemic district (Fulbaria) between 2010 and 2013 using a semi-ambulatory regimen for primary VL of 15mg/kg Liposomal Amphotericin-B (AmBisome) in three equal doses of 5mg/kg. The main objective of this study was to analyze the effectiveness and safety of this regimen after a 12 month follow-up period by retrospective analysis of routinely collected program data. A secondary objective was to explore risk factors for relapse.


Files in this item

Thumbnail
Name:
Lucero et al - 2015 - Effectiveness ...
Size:
246.3Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record